Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET mutant |
| Therapy | BYS10 |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET mutant | medullary thyroid carcinoma | predicted - sensitive | BYS10 | Case Reports/Case Series | Actionable | In a Phase I/II trial, treatment with BYS10 resulted in an objective response rate (ORR) of 62.5% and disease control rate (DCR) of 85% in advanced solid tumors (n=40), with an ORR of 50% and DCR of 100% in patients with medullary thyroid cancer harboring a RET mutation (n=4) (J Clin Oncol 2025 43: 16_suppl, 8601). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| First-in-human phase I/II study of BYS10 in patients (pts) with locally advanced or metastatic RET-altered solid tumors: Preliminary dose escalation results | Full reference... |